- Trials with a EudraCT protocol (699)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
699 result(s) found for: Triglycerides.
Displaying page 1 of 35.
EudraCT Number: 2007-001921-86 | Sponsor Protocol Number: S185.4.001 | Start Date*: 2007-07-19 | |||||||||||
Sponsor Name:Solvay Pharmaceuticals GmbH | |||||||||||||
Full Title: A double-blind, placebo-controlled, parallel-group, multi-center study to investigate the effect of Omacor (n-3 PUFA) on lipid parameters in HIV infected patients treated with HAART | |||||||||||||
Medical condition: HAART-induced hypertriglyeridemia in HIV infected subjects | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000872-40 | Sponsor Protocol Number: CLCQ908C2201 | Start Date*: 2012-11-13 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A pilot study to assess the efficacy and safety of LCQ908 alone and in combination with fenofibrate or Lovaza® in patients with severe hypertriglyceridemia | |||||||||||||
Medical condition: Non Familial Chylomicronemia Syndrome (Non-FCS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005535-68 | Sponsor Protocol Number: CLCQ908B2302 | Start Date*: 2012-05-08 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo controlled study to assess efficacy, safety and tolerability of LCQ908 in subjects with Familial Chylomicronemia Syndrome | |||||||||||||
Medical condition: Familial Chylomicronemia Syndrome (FCS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010520-25 | Sponsor Protocol Number: AMR-01-01-0016 | Start Date*: 2009-12-08 | ||||||||||||||||
Sponsor Name:Amarin Pharma Inc. | ||||||||||||||||||
Full Title: A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With an Open-Label Extension to Evaluate the Efficacy and Safety of AMR101 in Patients With Fasting Triglycer... | ||||||||||||||||||
Medical condition: Hypertriglyceridemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) DE (Completed) DK (Prematurely Ended) FI (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-001564-37 | Sponsor Protocol Number: AGMT_HIV1 | Start Date*: 2013-12-02 | |||||||||||
Sponsor Name:Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH | |||||||||||||
Full Title: One arm, Open label, Interventional, non-comparative Study to assess Changes in Lipids and Lipoproteins in HIV infected Women with Hyperlipidemia after Switch from boosted Protease Inhibitors to Ra... | |||||||||||||
Medical condition: HIV | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003353-24 | Sponsor Protocol Number: Hx-CD4-110 | Start Date*: 2007-04-25 | ||||||||||||||||
Sponsor Name:TenX Biopharma, Inc., | ||||||||||||||||||
Full Title: Open-label, Dose escalation, followed by Open-label, Single Arm, Multi-center Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with Mycosis Fungoides (stage IB-I... | ||||||||||||||||||
Medical condition: Refractory Mycosis Fungoides (stage IB-IVB) and Sézary Syndrome. The study population will be patients who are refractory to or intolerant to at least two prior therapies, one being Targretin, the... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) FR (Completed) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002316-24 | Sponsor Protocol Number: TAK-475/EC304 | Start Date*: 2005-09-27 | |||||||||||
Sponsor Name:Takeda Europe R &D Centre Ltd | |||||||||||||
Full Title: A placebo-controlled, double-blind, randomised study to evaluate the efficacy and safety of TAK-475 100mg in subjects with type 2 diabetes currently treated with lipid-lowering therapy. | |||||||||||||
Medical condition: treatment of patients with primary dyslipidaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FI (Completed) EE (Completed) SK (Completed) CZ (Completed) DE (Completed) DK (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003434-93 | Sponsor Protocol Number: ISIS-304801-CS16 | Start Date*: 2015-01-07 | |||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients with Hypertriglyceridemia | |||||||||||||
Medical condition: Hypertriglyceridemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Ongoing) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002852-13 | Sponsor Protocol Number: BPI-CT-005 | Start Date*: 2006-11-21 |
Sponsor Name:Bexel Pharmaceuticals Inc. | ||
Full Title: Double blind, placebo-controlled dose escalating, multiple dose study with two groups of 30 volunteers with type II diabetes to assess efficacy on glucose-profile, triglycerides and blood pressure ... | ||
Medical condition: dose escalating, multiple dose study with two groups of 30 volunteers with type II diabetes | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-000849-23 | Sponsor Protocol Number: HC-G-H-1403 | Start Date*: 2017-08-21 | |||||||||||
Sponsor Name:B. Braun Melsungen AG | |||||||||||||
Full Title: A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL TRIAL ON HOME PARENTERAL NUTRITION USING AN OMEGA-3 FATTY ACID ENRICHED MCT/LCT LIPID EMULSION | |||||||||||||
Medical condition: Chronic intestinal failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002715-10 | Sponsor Protocol Number: FAR-NP-2018-01 | Start Date*: 2019-02-08 |
Sponsor Name:Elisabet Leiva Badosa. Phamacy Department. Hospital Universitari de Bellvitge | ||
Full Title: RANDOMIZED, DOUBLE-BLIND, PILOT CLINICAL TRIAL TO COMPARE THE EFFICACY AND SAFETY OF FISH OIL-BASED INTRAVENOUS LIPID EMULSIONS IN HOSPITALIZED ADULT PATIENTS TREATED WITH TOTAL PARENTERAL NUTRITIO... | ||
Medical condition: Hypertriglyceridemia is a frequent metabolic complication associated with the administration of lipidic emulsion in total parenteral nutrition. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-000486-37 | Sponsor Protocol Number: 2013-000486-37 | Start Date*: 2013-07-16 | |||||||||||
Sponsor Name:Fundació Clínic per a la Recerca Biomèdica | |||||||||||||
Full Title: Rosuvastatin versus Protease Inhibitor Switching for Hypercholesterolaemia in HIV-infected Adults. | |||||||||||||
Medical condition: HIV AND HYPERCHOLESTEROLAEMIA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003253-15 | Sponsor Protocol Number: 58836 | Start Date*: 2017-01-25 |
Sponsor Name:Franciscus Gasthui | ||
Full Title: MODULATION OF POSTPRANDIAL LIPEMIA, INFLAMMATION, AND VASCULAR FUNCTION BY PCSK9 INHIBITION IN DIABETES. | ||
Medical condition: Diabetes mellitus type 2 | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-000614-12 | Sponsor Protocol Number: CV131-186 | Start Date*: 2005-11-28 |
Sponsor Name:Bristol Myers Squibb International Corporation | ||
Full Title: Irbesartan in the treatment of Hypertensive Patients with Metabolic Syndrome. Irbesartan en el tratamiento del paciente hipertenso con síndrome metabólico | ||
Medical condition: Hypertension, nos | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) IT (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-006550-31 | Sponsor Protocol Number: SEC-ES-BempeDACS-2021 | Start Date*: 2022-04-05 |
Sponsor Name:SPANISH SOCIETY OF CARDIOLOGY | ||
Full Title: Efficacy and Security of BempeDoic acid in Acute Coronary Syndrome | ||
Medical condition: Acute coronary syndrome with poor LDL-cholesterol control | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-005135-10 | Sponsor Protocol Number: 2005-151 | Start Date*: 2006-01-19 |
Sponsor Name:Jeppe Hagstrup Christensen | ||
Full Title: Omacor; omega-3-acid ethyl ester 90 (N-3 PUFA) and risk faktors in HIV infected patients treated with HAART with special focus on lipids | ||
Medical condition: Several investigations show that HIV infected patients have a higher risk for development of heart disease if treated with HAART. The investigation will evaluate the effect of fish oil on blood ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-024182-44 | Sponsor Protocol Number: NL3372110110 | Start Date*: 2011-01-12 | |||||||||||||||||||||
Sponsor Name: | |||||||||||||||||||||||
Full Title: Pilot study: Leucocyte actIvation and endothelial function after oral fat loading combined with VITamin D | |||||||||||||||||||||||
Medical condition: Endothelial function Leukocyte activation Triglyceride metabolism Skin autofluorescence | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003276-39 | Sponsor Protocol Number: PR(AG)293/2019 | Start Date*: 2019-11-12 |
Sponsor Name:VALL HEBRON UNIVERSITY HOSPITAL | ||
Full Title: Liver impairment recovery related to parenteral nutrition with omega-3 fatty acids: randomized clinical trial. | ||
Medical condition: Critically ill adult patients with parenteral nutrition and liver parameters altered. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000705-86 | Sponsor Protocol Number: 01-2020 | Start Date*: 2020-04-26 |
Sponsor Name:VALL HEBRON UNIVERSITY HOSPITAL | ||
Full Title: Control of inflammatory parameters with omega-3 fatty acid supplementation in adult patients with parenteral nutrition and respiratory infection by SARS-CoV-2: randomized clinical trial COVID-19 | ||
Medical condition: Critically ill adult patients with parenteral nutrition and respiratory infection by SARS-COV-2 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-006393-29 | Sponsor Protocol Number: V00312 CA 201 | Start Date*: 2008-04-15 | |||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT represented by Institut de Recherche Pierre Fabre | |||||||||||||
Full Title: A 4-week double-blind placebo-controlled pilot study, evaluating niacin-induced flushing and lipid parameter effects of V0002 CA 1g 3 capsules/day associated with Niaspan® (from 375 mg to 1000 mg) ... | |||||||||||||
Medical condition: Dyslipidemia with uncontrolled elevated triglycerides | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
